# Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)

> **NCT02597322** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 21 (actual)

## Conditions studied

- cT2a N0NxM0 Renal Tumor

## Interventions

- **DRUG:** AXITINIB

## Key facts

- **NCT ID:** NCT02597322
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-11
- **Final completion:** 2017-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597322, "Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02597322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*